Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Genomic Health, Inc.    GHDX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
31.43(c) 31.14(c) 31.15(c) 30.85(c) 30.98(c) Last
139 728 80 156 73 416 70 374 79 462 Volume
+0.51% -0.92% +0.03% -0.96% +0.42% Change
More quotes
Financials ($)
Sales 2017 349 M
EBIT 2017 -2,41 M
Net income 2017 -0,03 M
Finance 2017 49,3 M
Yield 2017 -
Sales 2018 388 M
EBIT 2018 13,6 M
Net income 2018 11,0 M
Finance 2018 66,3 M
Yield 2018 -
P/E ratio 2017 9 387,88
P/E ratio 2018 91,79
EV / Sales2017 2,94x
EV / Sales2018 2,60x
Capitalization 1 073 M
More Financials
Company
Genomic Health, Inc. engages in the development and global commercialization of genomic- based clinical laboratory services that analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions.Its uses a platform which translates a massive... 
More about the company
Surperformance© ratings of Genomic Health, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GENOMIC HEALTH, INC.
09/21 GENOMIC HEALTH : Presents Data Demonstrating Importance of Oncotype DX Breast Re..
09/21 GENOMIC HEALTH : and Biocartis Announce Agreement to Develop an Idylla IVD Oncot..
09/14 BIOCARTIS GROUP NV : Genomic Health and Biocartis Announce Agreement to Develop ..
09/13 GENOMIC HEALTH INC : Regulation FD Disclosure, Other Events, Financial Statement..
09/13 GENOMIC HEALTH : and Biocartis Announce Agreement to Develop an Idylla(TM) IVD O..
09/11 GENOMIC HEALTH : Presents Data Demonstrating Importance of Oncotype DX Breast Re..
08/31 GENOMIC HEALTH : Submission of Matters to a Vote of Security Holders (form 8-K/A..
08/31 GENOMIC HEALTH : Medicare Establishes Final Local Coverage Determination LCD for..
08/31 GENOMIC HEALTH : Continues to Pioneer Genomic-based Cancer Diagnostics with Mult..
08/30 GENOMIC HEALTH : to Present at the 2017 Wells Fargo Healthcare Conference
More news
Sector news : Biotechnology & Medical Research - NEC
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/20Kimberly J. Popovits Sells 5,000 Shares of Genomic Health, Inc. $GHDX Stock  
09/18$GHDX New SEC Document(s) for Genomic Health, Inc. From our Stock News Alerts.. 
09/18Jefferies Group LLC Reiterates Hold Rating for Genomic Health, Inc. $GHDX  
09/14$GHDX New SEC Document(s) for Genomic Health, Inc. From our Stock News Alerts.. 
09/14Genomic Health's hold rating reiterated at Jefferies Group LLC. $33.00 PT.  
More tweets
Qtime:18
News from SeekingAlpha
09/13 Genomic Health teams up with Biocartis to develop IVD version of Oncotype DX ..
08/24 Medicare to expand coverage of Genomic Health's prostate cancer test October ..
08/01 Genomic Health's (GHDX) CEO Kim Popovits on Q2 2017 Results - Earnings Call T..
08/01 Genomic Health misses by $0.02, misses on revenue
07/31 Notable earnings after Tuesday?s close
Chart GENOMIC HEALTH, INC.
Duration : Period :
Genomic Health, Inc. Technical Analysis Chart | GHDX | US37244C1018 | 4-Traders
Technical analysis trends GENOMIC HEALTH, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 32,1 $
Spread / Average Target 3,6%
EPS Revisions
Managers
NameTitle
Kimberly J. Popovits Chairman, President & Chief Executive Officer
G. Bradley Cole COO, CFO & Principal Accounting Officer
Steven Shak Chief Scientific Officer
Phillip G. Febbo Chief Medical Officer
Michael Vedda Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENOMIC HEALTH, INC.5.99%1 073
INCYTE CORPORATION14.56%24 235
QUINTILES IMS HOLDINGS INC24.44%20 267
LONZA GROUP57.01%19 853
CELLTRION, INC.--.--%15 738
ALNYLAM PHARMACEUTICALS, INC.204.06%10 359